Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone - PubMed (original) (raw)

Review

Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone

David W Oslin et al. Addict Biol. 2006 Sep.

Abstract

Alcohol dependence is one of the leading causes of morbidity worldwide, yet only a minority of those afflicted engages in treatment. While increasing access to treatment is an important public health approach, increasing the success of treatment is also likely to lead to greater engagement. However, alcohol dependence is a complex disorder likely to consist of several biological subtypes. Recent evidence from a number of different studies has suggested that genetic variation in the mu-opioid receptor has a significant influence on clinical presentation of alcohol problems and response to treatment with an opioid antagonist. Most notably, the A118G polymorphism of the mu-receptor gene has been demonstrated to predict clinical response to naltrexone in alcohol-dependent individuals. This article reviews the biological correlates and outlines a scientific agenda for better understanding the role of opioid neurotransmission in the etiology, maintenance and treatment of alcohol dependence.

PubMed Disclaimer

Similar articles

• Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.
  Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH; VA Cooperative Study #425 Study Group. Gelernter J, et al. Alcohol Clin Exp Res. 2007 Apr;31(4):555-63. doi: 10.1111/j.1530-0277.2007.00339.x. Alcohol Clin Exp Res. 2007. PMID: 17374034 Clinical Trial.
• Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
  Setiawan E, Pihl RO, Benkelfat C, Leyton M. Setiawan E, et al. Pharmacogenomics. 2012 Jul;13(10):1161-72. doi: 10.2217/pgs.12.99. Pharmacogenomics. 2012. PMID: 22909206 Review.
• Association of alcohol or other drug dependence with alleles of the mu opioid receptor gene (OPRM1).
  Kranzler HR, Gelernter J, O'Malley S, Hernandez-Avila CA, Kaufman D. Kranzler HR, et al. Alcohol Clin Exp Res. 1998 Sep;22(6):1359-62. Alcohol Clin Exp Res. 1998. PMID: 9756053
• Pharmacogenetic treatments for drug addiction: alcohol and opiates.
  Haile CN, Kosten TA, Kosten TR. Haile CN, et al. Am J Drug Alcohol Abuse. 2008;34(4):355-81. doi: 10.1080/00952990802122564. Am J Drug Alcohol Abuse. 2008. PMID: 18584566 Review.
• The μ-opioid receptor and treatment response to naltrexone.
  Thorsell A. Thorsell A. Alcohol Alcohol. 2013 Jul-Aug;48(4):402-8. doi: 10.1093/alcalc/agt030. Epub 2013 Mar 29. Alcohol Alcohol. 2013. PMID: 23543091 Review.

Cited by

• Translational models of addiction phenotypes to advance addiction pharmacotherapy.
  Ray LA, Nieto SJ, Grodin EN. Ray LA, et al. Ann N Y Acad Sci. 2023 Jan;1519(1):118-128. doi: 10.1111/nyas.14929. Epub 2022 Nov 17. Ann N Y Acad Sci. 2023. PMID: 36385614 Free PMC article. Review.
• Rational development of addiction pharmacotherapies: successes, failures, and prospects.
  Pierce RC, O'Brien CP, Kenny PJ, Vanderschuren LJ. Pierce RC, et al. Cold Spring Harb Perspect Med. 2012 Jun;2(6):a012880. doi: 10.1101/cshperspect.a012880. Cold Spring Harb Perspect Med. 2012. PMID: 22675669 Free PMC article. Review.
• OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.
  Mague SD, Blendy JA. Mague SD, et al. Drug Alcohol Depend. 2010 May 1;108(3):172-82. doi: 10.1016/j.drugalcdep.2009.12.016. Epub 2010 Jan 13. Drug Alcohol Depend. 2010. PMID: 20074870 Free PMC article. Review.
• Effects of the opioid receptor antagonist naltrexone on smoking and related behaviors in smokers preparing to quit: a randomized controlled trial.
  King A, Cao D, Zhang L, Rueger SY. King A, et al. Addiction. 2013 Oct;108(10):1836-44. doi: 10.1111/add.12261. Epub 2013 Jul 12. Addiction. 2013. PMID: 23714324 Free PMC article. Clinical Trial.
• Comparison of dehydroepiandrosterone (DHEA) and pregnanolone with existing pharmacotherapies for alcohol abuse on ethanol- and food-maintained responding in male rats.
  Hulin MW, Lawrence MN, Amato RJ, Weed PF, Winsauer PJ. Hulin MW, et al. Alcohol. 2015 Mar;49(2):127-38. doi: 10.1016/j.alcohol.2014.07.024. Epub 2015 Jan 6. Alcohol. 2015. PMID: 25620274 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program